Tecentriq-话题@MedSci - 梅斯（MedSci）

#Tecentriq#

40篇内容 | 1925人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1509600, encodeId=6606150960029, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, objectTitle=Tecentriq一线治疗转移性非小细胞肺癌，CHMP持积极意见, objectType=article, longId=209090, objectId=e891209090ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e891209090ea, replyNumber=0, likeNumber=0, createdTime=2021-03-29, rootId=0, userName=lfyang, userId=b2d810099674, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e891209090ea, moduleTitle=Tecentriq一线治疗转移性非小细胞肺癌，CHMP持积极意见, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e891209090ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509599, encodeId=c0a9150959907, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, objectTitle=PD-L1单抗Tecentriq联合VEGF单抗Avastin：在中国获准治疗常见的肝癌患者, objectType=article, longId=202660, objectId=e6f9202660eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6f9202660eb, replyNumber=0, likeNumber=77, createdTime=2020-10-31, rootId=0, userName=lfyang, userId=b2d810099674, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6f9202660eb, moduleTitle=PD-L1单抗Tecentriq联合VEGF单抗Avastin：在中国获准治疗常见的肝癌患者, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e6f9202660eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509598, encodeId=dd0215095986d, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, objectTitle=罗氏Tecentriq联合紫杉醇用于三阴性乳腺癌研究主要终点PFS未能达到, objectType=article, longId=198983, objectId=4d33198983b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d33198983b2, replyNumber=0, likeNumber=74, createdTime=2020-08-09, rootId=0, userName=lfyang, userId=b2d810099674, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d33198983b2, moduleTitle=罗氏Tecentriq联合紫杉醇用于三阴性乳腺癌研究主要终点PFS未能达到, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=4d33198983b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509597, encodeId=9c73150959e90, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, objectTitle=罗氏PD-L1单抗Tecentriq联合靶向疗法：获FDA批准治疗晚期黑色素瘤, objectType=article, longId=198563, objectId=ec5d198563ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec5d198563ab, replyNumber=0, likeNumber=80, createdTime=2020-08-03, rootId=0, userName=lfyang, userId=b2d810099674, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec5d198563ab, moduleTitle=罗氏PD-L1单抗Tecentriq联合靶向疗法：获FDA批准治疗晚期黑色素瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ec5d198563ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509596, encodeId=8393150959694, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, objectTitle=抗Trop-2的ADC药物Trodelvy联合PD-L1单抗Tecentriq：治疗尿道上皮癌和非小细胞肺癌, objectType=article, longId=197602, objectId=cbf019e602e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbf019e602e0, replyNumber=0, likeNumber=0, createdTime=2020-07-17, rootId=0, userName=lfyang, userId=b2d810099674, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbf019e602e0, moduleTitle=抗Trop-2的ADC药物Trodelvy联合PD-L1单抗Tecentriq：治疗尿道上皮癌和非小细胞肺癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=cbf019e602e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509595, encodeId=3ce91509595f3, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, objectTitle=罗氏的PD-L1单抗Tecentriq治疗晚期卵巢癌，III期研究失败, objectType=article, longId=197518, objectId=29ba19e518a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29ba19e518a8, replyNumber=0, likeNumber=69, createdTime=2020-07-16, rootId=0, userName=lfyang, userId=b2d810099674, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29ba19e518a8, moduleTitle=罗氏的PD-L1单抗Tecentriq治疗晚期卵巢癌，III期研究失败, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=29ba19e518a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509594, encodeId=96a415095946a, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, objectTitle=AACR 2020：PD-L1单抗Tecentriq联合卡铂和依托泊苷，可提高小细胞肺癌SCLC生存率, objectType=article, longId=196545, objectId=5a8619654517, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a8619654517, replyNumber=0, likeNumber=65, createdTime=2020-06-28, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a8619654517, moduleTitle=AACR 2020：PD-L1单抗Tecentriq联合卡铂和依托泊苷，可提高小细胞肺癌SCLC生存率, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=5a8619654517)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509593, encodeId=b5681509593bd, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, objectTitle=罗氏的PD-L1单抗Tecentriq，新辅助治疗三阴性乳腺癌III期成功, objectType=article, longId=196192, objectId=ea03196192c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea03196192c4, replyNumber=0, likeNumber=92, createdTime=2020-06-22, rootId=0, userName=lfyang, userId=b2d810099674, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea03196192c4, moduleTitle=罗氏的PD-L1单抗Tecentriq，新辅助治疗三阴性乳腺癌III期成功, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ea03196192c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509592, encodeId=d37d1509592ce, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, objectTitle=提供大幅折扣后，英国NICE批准了罗氏的PD-L1单抗Tecentriq治疗三阴性乳腺癌, objectType=article, longId=195499, objectId=9c0719549995, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c0719549995, replyNumber=0, likeNumber=117, createdTime=2020-06-10, rootId=0, userName=lfyang, userId=b2d810099674, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c0719549995, moduleTitle=提供大幅折扣后，英国NICE批准了罗氏的PD-L1单抗Tecentriq治疗三阴性乳腺癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=9c0719549995)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509591, encodeId=d8e4150959187, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, objectTitle=罗氏的Tecentriq/Avastin组合获得美国批准——用于无法切除或转移性肝癌的免疫疗法, objectType=article, longId=195322, objectId=25f219532272, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25f219532272, replyNumber=0, likeNumber=73, createdTime=2020-06-06, rootId=0, userName=lfyang, userId=b2d810099674, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25f219532272, moduleTitle=罗氏的Tecentriq/Avastin组合获得美国批准——用于无法切除或转移性肝癌的免疫疗法, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=25f219532272)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509590, encodeId=f4461509590b2, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, objectTitle=英国NICE批准罗氏的PD-L1单抗Tecentriq，用于治疗三阴性乳腺癌, objectType=article, longId=194614, objectId=d3b0194614fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3b0194614fc, replyNumber=0, likeNumber=177, createdTime=2020-05-24, rootId=0, userName=lfyang, userId=b2d810099674, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3b0194614fc, moduleTitle=英国NICE批准罗氏的PD-L1单抗Tecentriq，用于治疗三阴性乳腺癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d3b0194614fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509589, encodeId=7a6d150958966, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, objectTitle=美国批准PD-L1单抗Tecentriq，用于非小细胞肺癌的一线治疗, objectType=article, longId=194430, objectId=b3b9194430bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3b9194430bd, replyNumber=0, likeNumber=71, createdTime=2020-05-21, rootId=0, userName=lfyang, userId=b2d810099674, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3b9194430bd, moduleTitle=美国批准PD-L1单抗Tecentriq，用于非小细胞肺癌的一线治疗, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b3b9194430bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509588, encodeId=7fe71509588ed, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, objectTitle=ASCO 2020：罗氏的TIGIT单抗tiragolumab与PD-L1单抗Tecentriq联合，延长了非小细胞肺癌患者生存期, objectType=article, longId=194315, objectId=4a69194315ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a69194315ed, replyNumber=0, likeNumber=60, createdTime=2020-05-19, rootId=0, userName=lfyang, userId=b2d810099674, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a69194315ed, moduleTitle=ASCO 2020：罗氏的TIGIT单抗tiragolumab与PD-L1单抗Tecentriq联合，延长了非小细胞肺癌患者生存期, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=4a69194315ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509587, encodeId=d2e1150958e2c, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, objectTitle=罗氏的PD-L1单抗Tecentriq在美国获得优先审查, objectType=article, longId=188787, objectId=ec53188e8791, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec53188e8791, replyNumber=0, likeNumber=73, createdTime=2020-02-27, rootId=0, userName=lfyang, userId=b2d810099674, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec53188e8791, moduleTitle=罗氏的PD-L1单抗Tecentriq在美国获得优先审查, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ec53188e8791)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509586, encodeId=f38e1509586cd, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, objectTitle=喜讯！罗氏的Tecentriq在中国获得批准，用于治疗广泛期小细胞肺癌, objectType=article, longId=188190, objectId=a74718819031, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a74718819031, replyNumber=0, likeNumber=72, createdTime=2020-02-17, rootId=0, userName=lfyang, userId=b2d810099674, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a74718819031, moduleTitle=喜讯！罗氏的Tecentriq在中国获得批准，用于治疗广泛期小细胞肺癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a74718819031)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509585, encodeId=524915095858d, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, objectTitle=罗氏2019年财报：Tecentriq、Hemlibra增长迅猛，中国区增速36%, objectType=article, longId=187092, objectId=a76118e0920c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a76118e0920c, replyNumber=0, likeNumber=72, createdTime=2020-02-03, rootId=0, userName=lfyang, userId=b2d810099674, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a76118e0920c, moduleTitle=罗氏2019年财报：Tecentriq、Hemlibra增长迅猛，中国区增速36%, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a76118e0920c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509584, encodeId=c08615095843f, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, objectTitle=因价格问题，NICE拒绝将罗氏的PD-L1单抗Tecentriq联合化疗用于广泛期小细胞肺癌, objectType=article, longId=185527, objectId=8ca718552e25, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ca718552e25, replyNumber=0, likeNumber=74, createdTime=2020-01-03, rootId=0, userName=lfyang, userId=b2d810099674, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ca718552e25, moduleTitle=因价格问题，NICE拒绝将罗氏的PD-L1单抗Tecentriq联合化疗用于广泛期小细胞肺癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=8ca718552e25)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509583, encodeId=b5c41509583e2, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, objectTitle=罗氏的PD-L1单抗Tecentriq组合显着降低黑色素瘤患者的疾病进展和死亡风险, objectType=article, longId=184877, objectId=fe901848e7f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe901848e7f2, replyNumber=0, likeNumber=79, createdTime=2019-12-19, rootId=0, userName=lfyang, userId=b2d810099674, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe901848e7f2, moduleTitle=罗氏的PD-L1单抗Tecentriq组合显着降低黑色素瘤患者的疾病进展和死亡风险, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=fe901848e7f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509582, encodeId=bec9150958251, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, objectTitle=罗氏的PD-L1单抗Tecentriq获得FDA批准用于治疗转移性非鳞状非小细胞肺癌, objectType=article, longId=184290, objectId=431b184290f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=431b184290f9, replyNumber=0, likeNumber=78, createdTime=2019-12-08, rootId=0, userName=lfyang, userId=b2d810099674, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=431b184290f9, moduleTitle=罗氏的PD-L1单抗Tecentriq获得FDA批准用于治疗转移性非鳞状非小细胞肺癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=431b184290f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509581, encodeId=f8f515095815f, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, objectTitle=罗氏的PD-L1单抗Tecentriq联合Avastin在III期肝癌试验中将死亡风险降低了40％以上, objectType=article, longId=183550, objectId=84a4183550aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84a4183550aa, replyNumber=0, likeNumber=73, createdTime=2019-11-26, rootId=0, userName=lfyang, userId=b2d810099674, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84a4183550aa, moduleTitle=罗氏的PD-L1单抗Tecentriq联合Avastin在III期肝癌试验中将死亡风险降低了40％以上, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=84a4183550aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Tecentriq

2020-05-29

lfyang (审核中...)

前往app查看评论内容

#Tecentriq#

Tecentriq一线治疗转移性非小细胞肺癌，CHMP持积极意见

2021-03-29

lfyang (审核中...)

前往app查看评论内容

#Tecentriq#

PD-L1单抗Tecentriq联合VEGF单抗Avastin：在中国获准治疗常见的肝癌患者

2020-10-31

lfyang (审核中...)

前往app查看评论内容

#Tecentriq#

罗氏Tecentriq联合紫杉醇用于三阴性乳腺癌研究主要终点PFS未能达到

2020-08-09

lfyang (审核中...)

前往app查看评论内容

#Tecentriq#

罗氏PD-L1单抗Tecentriq联合靶向疗法：获FDA批准治疗晚期黑色素瘤

2020-08-03

lfyang (审核中...)

前往app查看评论内容

#Tecentriq#

抗Trop-2的ADC药物Trodelvy联合PD-L1单抗Tecentriq：治疗尿道上皮癌和非小细胞肺癌

2020-07-17

lfyang (审核中...)

前往app查看评论内容

#Tecentriq#

罗氏的PD-L1单抗Tecentriq治疗晚期卵巢癌，III期研究失败

2020-07-16

智智灵药 (审核中...)

前往app查看评论内容

#Tecentriq#

AACR 2020：PD-L1单抗Tecentriq联合卡铂和依托泊苷，可提高小细胞肺癌SCLC生存率

2020-06-28

lfyang (审核中...)

前往app查看评论内容

#Tecentriq#

罗氏的PD-L1单抗Tecentriq，新辅助治疗三阴性乳腺癌III期成功

2020-06-22

lfyang (审核中...)

前往app查看评论内容

#Tecentriq#

提供大幅折扣后，英国NICE批准了罗氏的PD-L1单抗Tecentriq治疗三阴性乳腺癌

2020-06-10

lfyang (审核中...)

前往app查看评论内容

#Tecentriq#

罗氏的Tecentriq/Avastin组合获得美国批准——用于无法切除或转移性肝癌的免疫疗法

2020-06-06

lfyang (审核中...)

前往app查看评论内容

#Tecentriq#

英国NICE批准罗氏的PD-L1单抗Tecentriq，用于治疗三阴性乳腺癌

2020-05-24

lfyang (审核中...)

前往app查看评论内容

#Tecentriq#

美国批准PD-L1单抗Tecentriq，用于非小细胞肺癌的一线治疗

2020-05-21

lfyang (审核中...)

前往app查看评论内容

#Tecentriq#

ASCO 2020：罗氏的TIGIT单抗tiragolumab与PD-L1单抗Tecentriq联合，延长了非小细胞肺癌患者生存期

2020-05-19

lfyang (审核中...)

前往app查看评论内容

#Tecentriq#

罗氏的PD-L1单抗Tecentriq在美国获得优先审查

2020-02-27

lfyang (审核中...)

前往app查看评论内容

#Tecentriq#

喜讯！罗氏的Tecentriq在中国获得批准，用于治疗广泛期小细胞肺癌

2020-02-17

lfyang (审核中...)

前往app查看评论内容

#Tecentriq#

罗氏2019年财报：Tecentriq、Hemlibra增长迅猛，中国区增速36%

2020-02-03

lfyang (审核中...)

前往app查看评论内容

#Tecentriq#

因价格问题，NICE拒绝将罗氏的PD-L1单抗Tecentriq联合化疗用于广泛期小细胞肺癌

2020-01-03

lfyang (审核中...)

前往app查看评论内容

#Tecentriq#

罗氏的PD-L1单抗Tecentriq组合显着降低黑色素瘤患者的疾病进展和死亡风险

2019-12-19

lfyang (审核中...)

前往app查看评论内容

#Tecentriq#

罗氏的PD-L1单抗Tecentriq获得FDA批准用于治疗转移性非鳞状非小细胞肺癌

2019-12-08

lfyang (审核中...)

前往app查看评论内容

#Tecentriq#

罗氏的PD-L1单抗Tecentriq联合Avastin在III期肝癌试验中将死亡风险降低了40％以上

2019-11-26

科室
- - 订阅+
  - 更多科室
工具
服务